Fortis Healthcare Limited announced its financial results for the second quarter and first half of Fiscal Year 2027. The company reported a consolidated revenue of INR 2,735 crore for the quarter, marking a 17.3% increase over Q2 FY26. The hospital business saw an 18.6% revenue growth, while diagnostics revenue increased by 12.2%. Consolidated operating EBITDA grew by 19.2% to INR 663 crore.
Fortis Healthcare Announces Strong Q2 FY27 Financial Results
Fortis Healthcare Limited has reported robust financial performance for the second quarter and the first half of Fiscal Year 2027, ending September 30, 2026. The company experienced a notable increase in both revenue and profitability, driven by sustained growth across its hospital and diagnostics divisions.
Q2 FY27 Performance Highlights
For the second quarter of FY27, Fortis Healthcare’s consolidated revenue reached INR 2,735 crore, representing a significant growth of 17.3% compared to INR 2,332 crore in the corresponding quarter of FY26. The hospital business emerged as a key growth driver, with revenues rising by 18.6% to INR 2,340 crore. The diagnostics segment also demonstrated healthy performance, with gross revenues of INR 448 crore, an increase of 12.2% over INR 400 crore in Q2 FY26.
Consolidated operating EBITDA, excluding ESOP expenses, saw a substantial increase of 19.2%, reaching INR 663 crore. This led to an improvement in operating EBITDA margins to 24.2% in Q2 FY27 from 23.9% in the previous year’s quarter. The hospital business reported operating EBITDA of INR 545 crore with margins improving to 23.3%, while the diagnostics business also recorded a marginal improvement in operating EBITDA margin to 26.2%.
Consolidated profit after tax, excluding exceptional items, increased by 4% to INR 317 crore compared to INR 305 crore in Q2 FY26.
H1 FY27 Performance Overview
During the first half of FY27, consolidated revenue stood at INR 5,280 crore, a growth of 17.4% over H1 FY26. The hospital business contributed significantly with an 18.8% revenue increase to INR 4,527 crore, while the diagnostics business reported gross revenues of INR 855 crore, an 11.2% growth.
Consolidated profit after tax, excluding exceptional items, grew by 3.8% to INR 581 crore in H1 FY27 compared to INR 559 crore in H1 FY26.
Key Business Developments
The company highlighted the steady growth in its hospital business, with occupancy improving to 72% and ARPP growing by 6.8%. Key specialties like renal sciences, neuro sciences, and orthopedics showed strong year-on-year revenue growth of 27%, 28%, and 30% respectively. Fifteen hospital facilities reported operating EBITDA margins exceeding 20%, contributing about 84% of hospital revenues.
International business revenue grew by 12.4% to INR 190 crore, contributing approximately 8% to overall revenues.
In the diagnostics segment, network expansion continued, with customer touch points reaching 4,551. Revenue from wellness and specialized testing grew by 28% and 14% respectively. The Wellness segment’s contribution to overall revenue improved to 15%, and the B2C segment’s contribution increased to 54%.
The company also mentioned network expansion initiatives, including the acquisition of a 110-bedded hospital in Bangalore and a long-term healthcare services agreement for a 400-bedded hospital in New Delhi.
Financial Position
On the balance sheet front, the company’s net debt stood at INR 2,188 crore as of September 30, 2026, with a healthy net debt-to-EBITDA ratio of 0.87x.
Source: BSE
